Kohjin Bio Co.,Ltd. AI Stock Analysis
Want to see JP:177A full AI Analyst Report?
Kohjin Bio Co.,Ltd. (177A) AI Stock Analysis
Kohjin Bio Co.,Ltd.
(TSE/TYO:177A)
The overall score is very low, reflecting significant fundamental and technical headwinds. The primary drag is the company's deteriorating financial performance, marked by falling revenue, collapsing margins, and negative free cash flow. This is compounded by a persistently bearish technical trend, with the stock trading well below all major moving averages. The high P/E ratio further adds risk, as the valuation remains elevated despite worsening business conditions.
Kohjin Bio Co.,Ltd. (177A) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.42B
- Dividend Yield
- 1.49%
- Average Volume (3M)
- 3,131
- Price to Earnings (P/E)
- 27.0
- Beta (1Y)
- 0.43
- Revenue Growth
- -9.46%
- EPS Growth
- -82.25%
- Country
- Japan
- Employees
- 176
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Kohjin Bio Co.,Ltd. Business Overview & Revenue Model
Company Description
Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materi...
How the Company Makes Money
null
Kohjin Bio Co.,Ltd. Financial Statement Overview
Summary
Financial performance is weak, driven by a 4.7% revenue decline, sharp margin compression, and negative free cash flow. The solid balance sheet with low leverage provides some stability, but deteriorating profitability and weak cash generation are significant concerns.
Income Statement
38NegativeBalance Sheet
55NeutralCash Flow
30Negative| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.18B | 5.21B | 4.94B | 4.77B | 4.74B | 3.95B |
| Gross Profit | 2.31B | 2.37B | 1.86B | 1.88B | 2.45B | 2.04B |
| EBITDA | 1.26B | 1.41B | 766.46M | 958.10M | 1.44B | 1.14B |
| Net Income | 714.00M | 794.76M | 251.02M | 384.00M | 829.79M | 587.67M |
Balance Sheet | ||||||
| Total Assets | 9.17B | 9.12B | 8.90B | 6.64B | 6.20B | 5.60B |
| Cash, Cash Equivalents and Short-Term Investments | 3.10B | 3.15B | 2.49B | 1.73B | 1.46B | 1.73B |
| Total Debt | 1.99B | 2.39B | 2.19B | 2.47B | 2.10B | 2.23B |
| Total Liabilities | 3.46B | 3.34B | 2.96B | 3.30B | 3.18B | 3.38B |
| Stockholders Equity | 5.71B | 5.78B | 5.95B | 3.34B | 3.02B | 2.22B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 28.05M | -280.78M | 260.88M | -99.57M | 559.44M |
| Operating Cash Flow | 0 | 915.55M | 698.51M | 823.68M | 461.15M | 762.98M |
| Investing Cash Flow | 0 | -1.09B | -867.67M | -577.35M | -575.46M | 82.78M |
| Financing Cash Flow | 0 | 1.38B | -320.76M | -1.35M | -172.21M | -360.17M |
Kohjin Bio Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:177A, the sentiment is Negative. The current price of 670.00 is below the 20-day moving average (MA) of 758.75, below the 50-day MA of 803.02, and below the 200-day MA of 1047.60, indicating a bearish trend. The MACD of -35.01 indicates Positive momentum. The RSI at 25.40 is Positive, neither overbought nor oversold. The STOCH value of 12.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:177A.
Kohjin Bio Co.,Ltd. Peers Comparison
Overall Rating
JP:497847Neutral
JP:777442Neutral- JP:177A41Neutral
JP:777639Underperform
JP:459938Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4978 | 47Neutral | JPY 12.29B | -23.75 | ― | ― | -8.23% | -48.10% |
| JP:7774 | 42Neutral | JPY 27.61B | -74.80 | ― | ― | 17.05% | 10.47% |
| JP:177A | 41Neutral | JPY 3.45B | 27.00 | ― | 1.49% | -9.46% | -82.25% |
| JP:7776 | 39Underperform | JPY 6.78B | -5.83 | ― | ― | -56.16% | 3.12% |
| JP:4599 | 38Underperform | JPY 7.46B | -4.01 | ― | ― | ― | 4.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:177A | Kohjin Bio Co.,Ltd. | 670.00 | -882.89 | -56.85% | |
| JP:4599 | StemRIM Inc. | 119.00 | -168.00 | -58.54% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -52.00 | -32.30% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 662.00 | 172.00 | 35.10% | |
| JP:7776 | CellSeed Inc. | 169.00 | -241.00 | -58.78% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026